- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04692831
Testing a New Imaging Agent to Identify Cancer
April 15, 2024 updated by: Memorial Sloan Kettering Cancer Center
Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Randy Yeh, MD
- Phone Number: 212-639-3776
- Email: yehr@mskcc.org
Study Contact Backup
- Name: Jason Lewis, PhD
- Phone Number: 646-888-3038
- Email: lewisj2@mskcc.org
Study Locations
-
-
California
-
Newport Beach, California, United States, 92663
- Not yet recruiting
- PATTY AND GEORGE HOAG CANCER CENTER (Data or Specimen Analysis Only)
-
Contact:
- Gary Ulaner, MD, PhD
- Phone Number: 949-722-6237
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
Rockville Centre, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau (Limited Protocol Activites)
-
Contact:
- Randy Yeh, MD
- Phone Number: 212-639-3776
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease
Note: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization [ISH]-negative, including FISH.
- Biopsy proven primary malignancy or metastatic disease
- At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment
- Age 18 years or greater
- ECOG performance of 0-2
Exclusion Criteria:
- Creatinine > 2 times normal limit (obtained with 8 weeks of enrollment)
- AST/ALT > 2 times normal limit (obtained with 8 weeks of enrollment)
- Life expectancy < 3 months
- Pregnancy or lactation
- Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HER2-positive malignancy
Participants will have a diagnosis of HER2-positive malignancy
|
Patients will receive 89Zr-ss-pertuzumab.
89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction.
In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients.
Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
|
Experimental: HER2-low malignancy
Participants will have a diagnosis of HER2-low malignancy
|
Patients will receive 89Zr-ss-pertuzumab.
89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction.
In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients.
Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate clinical safety of 89Zr-ss-pertuzumab
Time Frame: Up to 20 months
|
CTCAE Version 5 will be utilized for toxicity evaluation
|
Up to 20 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Randy Yeh, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2020
Primary Completion (Estimated)
November 30, 2024
Study Completion (Estimated)
November 30, 2024
Study Registration Dates
First Submitted
December 30, 2020
First Submitted That Met QC Criteria
December 30, 2020
First Posted (Actual)
January 5, 2021
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 15, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-275
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials.
The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov
when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required.
Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication.
Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals.
Requests may be made to: crdatashare@mskcc.org.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-positive Metastatic Breast Cancer
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHER2-positive Metastatic Breast CancerChina
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
Clinical Trials on 89Zr-ss-pertuzumab PET/CT
-
Memorial Sloan Kettering Cancer CenterUnited States Department of Defense; Genentech, Inc.CompletedBreast Cancer Metastases | HER2 Positive BreastUnited States
-
Institut Cancerologie de l'OuestATONCOCompleted
-
Radboud University Medical CenterImaginAb, Inc.RecruitingPET Imaging | Lymphopenia Due to COVID-19 | T-cellNetherlands
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingDLBCL | Large B-cell LymphomaUnited States
-
Institut Cancerologie de l'OuestTelix Pharmaceutical; SIRIC ILIADRecruiting
-
Memorial Sloan Kettering Cancer CenterCompletedHER2-positive Carcinoma | HER2-positive Primary MalignancyUnited States
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell UniversityCompleted
-
Memorial Sloan Kettering Cancer CenterWithdrawn
-
Aplagon OyTRACER Europe BVRecruitingPeripheral Arterial Occlusive Disease | Critical Limb IschemiaNetherlands